Navigation Links
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Date:2/14/2008

clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we will fail to present final safety and efficacy data from a Phase 1, Part 3 multiple ascending dose study, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that we will fail to initiate a Phase 2b combination study of R7128 with Pegasys plus Copegus in the fourth calendar quarter of 2008, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filing
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. CEL-SCI Corporation Reports First Quarter Financial Results
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... September 19, 2014 A recent study ... that older patients with higher levels of vitamin D will ... includes more mobility, better ability to perform daily tasks, and ... at the University of Alberta’s School of Public Health. ... is vitally important to our bodies,” said Dr. Arash Bereliani, ...
(Date:9/19/2014)... Wisconsin (PRWEB) September 19, 2014 QueenBeeTickets.com has ... the Web. With a new tour set to begin on ... to be big sellers on the secure website. , ... for John Mellencamp’s tour at QueenBeeTickets.com. , The Plain Spoken ... all set to obtain seats for a show coming to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Indiana Fiber ... Provider, announces the expansion of its Fiber Transport Services, ... in Chicago. By establishing a PoP at Cermak, ... Enterprise organizations looking for high bandwidth fiber transport service ... According to IFN Vice President of Sales and Marketing ...
(Date:9/19/2014)... Monroe, OH (PRWEB) September 19, 2014 ... Family YMCA to bring Health and Well-Being Coach Christi ... fitness career began after surviving brain tumors and gaining weight ... trainer, Hall began weight training and learning about nutrition. One ... and blood sugar, and increased her strength, endurance and cardio. ...
(Date:9/19/2014)... Va. (PRWEB) September 19, 2014 It isn’t ... Forest, a skilled nursing center that offers rehabilitation and assisted ... will this weekend when a young couple marries on site ... with their combined 140 years of marriage have helped showcase ... Sarah Horky, 18, and Dan Eads, 20, may have only ...
Breaking Medicine News(10 mins):Health News:Vitamin D Linked to Improved Quality of Life for Those over 50 2Health News:Vitamin D Linked to Improved Quality of Life for Those over 50 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3
... A new study by researchers at the University at Buffalo ... the September issue of the journal Pain , reveals ... adversity in your life can be protective and beneficial. These ... doctor,s offices or health clinics, says the study,s author Mark ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, Aug. 5 ... see two fingers held up just one foot in front of ... village. Nor could she see an eye chart from a similarly ... laid hands on her and prayed for less than a minute, ...
... dressed in overcoat, pockets filled with stones, walked into a ... Hemingway put his shotgun to his head and pulled the ... 44 years later celebrated authors, all who University of Alberta ... stature was not the fate of a group of 18th ...
... agents may play an important role in maintaining ... studies in Clinical Gastroenterology and Hepatology , ... (AGA) Institute. "Post-surgical recurrence of Crohn,s ... traditional drugs used to treat the naturally occurring ...
... of Louisville has received a $3.15 million grant from ... to support the UofL James Graham Brown Cancer Center ... will be matched with state "Bucks for Brains" funding ... Cancer Research Program (OCRP). "When we established this ...
... OAK BROOK, Ill. August 5, 2010 A ... a split-dosage schedule of bowel (colon) preparation is the ... performed within six to eight hours of the end ... those performed more than eight hours after the end ...
Cached Medicine News:Health News:A little adversity bodes well for those with chronic back pain 2Health News:Can Hands-On Prayer Help Heal? 2Health News:Can Hands-On Prayer Help Heal? 3Health News:Secularization of suicide meant callous mockery of writers' deaths 2Health News:Studies offer encouraging data on preventing Crohn's disease recurrence 2Health News:Studies offer encouraging data on preventing Crohn's disease recurrence 3Health News:UofL receives $3.15 million grant from Helmsley Charitable Trust 2Health News:UofL receives $3.15 million grant from Helmsley Charitable Trust 3Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 2Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 3Health News:Study shows splitting bowel preparation dosage is most effective cleansing method before colonoscopy 4
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Control is a bilevel liquid ... performance of the most widely ... A weak positive and a ... monitor the performance of your ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Medicine Products: